A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
Public ClinicalTrials.gov record NCT03088878. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Study identification
- NCT ID
- NCT03088878
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Oncternal Therapeutics, Inc
- Industry
- Enrollment
- 95 participants
Conditions and interventions
Conditions
Interventions
- Cirmtuzumab (2-16 kg/mg) plus Ibrutinib Drug
- Cirmtuzumab (300mg) plus Ibrutinib Drug
- Cirmtuzumab (600 mg) plus ibrutinib Drug
- Cirmtuzumab (RDR) plus ibrutinib Drug
- Cirmtuzumab plus ibrutinib Drug
- Ibrutinib alone Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2, 2018
- Primary completion
- Sep 24, 2024
- Completion
- Sep 24, 2024
- Last update posted
- Feb 11, 2025
2018 – 2024
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope (City of Hope National Medical Center, City of Hope Medical Center) | Duarte | California | 91010 | — |
| Sanford Stem Cell Clinical Center at UCSD | La Jolla | California | 92093 | — |
| UC Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| Yale Cancer Center | New Haven | Connecticut | 06510 | — |
| Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | — |
| Louisiana State University Health New Orleans (NCI Community Oncology Research Program) | New Orleans | Louisiana | 70112 | — |
| Hackensack Meridian Health, John Theurer Cancer Center | Hackensack | New Jersey | 07601 | — |
| Northwell Health | New Hyde Park | New York | 11042 | — |
| Manhattan Hematology Oncology Research Foundation, Inc. | New York | New York | 10016 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| The Christ Hospital Lindner Research Center | Cincinnati | Ohio | 45219 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03088878, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 11, 2025 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03088878 live on ClinicalTrials.gov.